TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants With Molecular Response (MR4^0) at 18 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Impact
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Visual Acuity Monocular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity Binocular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Assessment of Lens Comfort
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Assessment of Quality of Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dosage/schedule of Mircera treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trust and Perceived Manipulativeness of doctor and medical institution
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Views on altruistic nature of organ donation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Vegetable Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of oral contraceptives
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Premature Withdrawal Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Success of in-hospital cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of myonecrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of drug prototype-meloxicam in tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular pressure examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Corneal fluorescence staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skill Retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of children receiving all recommended doses of the core vaccine series
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of children receiving all recommended vaccines doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of children receiving appropriate influenza vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in worst pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (ORR) for Cohorts B and C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate (ORR) for Cohort D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiographic Progression Free Survival (rPFS) for Cohorts B and C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Radiographic Progression-Free Survival (rPFS) for Cohort D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of HKA Angle Outliers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinonasal-Outcomes Test-22 (SNOT-22) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of carotid artery calcifications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Electrical Activity of the Diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neuro-Mechanical Coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neuro-ventilatory Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neural breathing pattern (Tidal Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neural breathing pattern (Respiratory Rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Renal Plasma Flow (RPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Amyloid physiological parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wound area percent change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in number of residual events between high and low pressure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variance in average obstruction of the upper airway during sleep measured by Obstruction Index (OI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Endurance exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Harris Hip Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nonarthritic Hip Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: International Hip Outcome Tool-12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form 12 Mental
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Short Form 12 Physical
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Veterans RAND 12-Item Health Survey Mental
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Veterans RAND 12-Item Health Survey Physical
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Subjects With Immediate Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Subjects With Solicited Local Reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number and Percentage of Subjects With Occurrence of Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in CFQ-R Respiratory Domain Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disposition of sibutramine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NeuroCognitive Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional Magnetic Resonance Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with preferred anesthesia technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose of monoclonal antibody 3F8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-neuroblastoma effects of monoclonal antibody 3F8 and sargramostim (GM-CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of persistent HPV-16/18 infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Reporting One or More Adverse Drug Reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting One or More Serious Adverse Drug Reactions (SADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Falls Efficacy Scale (FES)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Balance and Gait Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinical episodes of malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of treatment failure at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of patients with negative CTCs and DTCs after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Development of acute renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Return to Work (RTW) at 3 months follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Return to Work (RTW) at 1 year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Return to Work (RTW) at 2 year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient's well-being symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stages of Change Readiness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Therapeutic Alliance
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Agreement between QFT-G and TST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Protective antibody titers against influenza H1N1 2009
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lowest S/F Oxygen Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median local progression-free-survival
Endpoint domain: Mortality/survival
Primary endpoint: Endotoxin Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotion Regulation Content Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Tasks of Executive Control
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Physical activity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: DAS28 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in hospital readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Achievement of 50% Nutritional Needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in intestinal microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduced Parasite Multiplication Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of participants having an improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cardiac vagal tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Growth of atrophic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in downstream effector levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSHR mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physical Activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Patients Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: puncture pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cases with Papilloma Recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: mean fold increase in peripheral CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Iron study labs (ferritin, Total Iron Binding Capacity, and Iron lab)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin and Hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adherence to medical regimen/treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events following Single ascending dose (SAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events following multiple ascending dose (MAD)
Endpoint domain: Adverse events/effects
Primary endpoint: Short term outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulating stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPECT Imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Have a Defined Increase in 24-hour Urine Volume From Baseline to Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants With A Serum Potassium <3.2 mEq/L at Week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants Reporting a Severe or Very Severe Rash Attributable to Furosemide at Week 1
Endpoint domain: Adverse events/effects
Primary endpoint: Mean bone mineral density of the lumbar spine (L 1-4 BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of women with similar characteristics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Transcutaneous level carbon dioxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-second chair number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 4 stage balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local and systemic adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of patients needing endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of subtherapeutic antiinfective concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of meropenem concentration in serum to the concentration in brain fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subtherapeutic antiinfective concentrations during hemoadsorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physiological Anxiety in Response to Food Images as assessed by Skin Conductance Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physiological Anxiety in Response to Food Images as assessed by Heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in amount of high calorie diet consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumor Uptake of 64Cu-DOTA-hT4.66-M5A at Day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: local and CNS relapse rate
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of refractory active ischemic digital ulcers healed (complete or partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite endpoint combining healing (complete or partial) without recurrence and without local or general complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Electrical impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity determined by anti-WN/DEN4 neutralizing antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resolution of Clostridium difficile-Associated disease (CDAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Achieving DAS28-ESR Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Concentration of Ethacrynic Acid and its conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Excretion Rates of Ethacrynic Acid and its conjugates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower limb motor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of patients' experience from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flow determination in distal tubing of VP shunt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to use physical violence during next partner conflict
Endpoint domain: Adverse events/effects
Primary endpoint: Success rate of AVATAR system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bioequivalence of risedronate tablets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change of carotid intimal medial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Development of thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: decrease of DSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from baseline in alcohol craving score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) Determination by Number of Participants With Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: RASS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in Control of Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MS 54 Quality of Life scale physical health score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MS 54 Quality of Life scale mental health score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Timeliness of enrolling eligible patients
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bacterial HAP/VAP episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Polysomnographic sleep features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Change in Buss-Perry Aggression Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protective Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Protection Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of Complete Remission and Complete Remission With Incomplete Recovery of Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart activity on ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of remainders
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of sarcopenia on admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle mass (the anterior rectus femoris muscle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Terminal phase half-life (T-HALF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Presenting With a Confirmed Microbial Blood Stream Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Visual Memory Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Verbal Memory Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Durability of virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-procedural implant safety of iCoapsys System
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-procedural safety of the iCoapsys System
Endpoint domain: Adverse events/effects
Primary endpoint: Intra-procedural MR reduction with the iCoapsys System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed serum concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes